ERBB2 and breast cancer: To evaluate serum HER2 (sHER2) as a potential biomarker for breast cancer response, we examined the serum samples from patients treated with neratinib or trastuzumab combined with paclitaxel obtained from the I-SPY2 neoadjuvant trial.